Clinical Trial Update: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) [Phase 3]

View source ↗

Summary

The Phase 3 trial MK-0822-050 evaluating odanacatib in postmenopausal osteoporosis previously treated with alendronate has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis, Postmenopausal Osteoporosis | Phase 3 | Status: WITHDRAWN